IGKV2D-24: A Potential Drug Target and Biomarker (G28885)

Target Name: IGKV2D-24

NCBI ID: G28885

Other Name(s): IGKV2D24 | immunoglobulin kappa variable 2D-24 (non-functional) | A7 | Immunoglobulin kappa variable 2D-24 (non-functional)

IGKV2D-24: A Potential Drug Target and Biomarker

Introduction

The IGKV2D24 gene has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, mental health conditions, and autoimmune diseases. The IGKV2D24 gene is a member of the IGKV family, which is known to be involved in various cellular processes. , including inflammation, stress response, and neurotransmission. The IGKV2D24 gene has been shown to play a role in the regulation of ion channels, which are critical for the proper functioning of neuronal cells.

Disease-Related IGKV2D24 Expression

Neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neurodegeneration. These disorders are associated with the misfolding of proteins, which can lead to the formation of toxic species that cause damage to the brain. IGKV2D24 has been shown to be involved in the regulation of the misfolding of proteins and has been implicated in the development and progression of neurodegenerative disorders.

IGKV2D24 has also been shown to be involved in the regulation of ion channels, which play a critical role in the proper functioning of neuronal cells. Ion channels are responsible for the rapid and efficient transmission of electrical signals through the nervous system. The misfunction of ion channels has been implicated in a number of neurodegenerative disorders, including Alzheimer's disease.

Mental Health Conditions

Mental health conditions, such as depression and anxiety, are characterized by the excessive or persistent symptoms of emotional distress, and can have a significant impact on an individual's daily life. IGKV2D24 has been shown to be involved in the regulation of ion channels and has been implicated in the development and progression of mental health conditions.

IGKV2D24 has also been shown to play a role in the regulation of the activity of serotonin receptors, which are involved in regulation mood. IGKV2D24 has also been shown to play a role in the regulation of the activity of dopamine receptors, which are involved in the motivation and pleasure associated with drug use.

Autoimmune Diseases

Autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, are characterized by the immune system attacking the body's own tissues and causing inflammation and damage. IGKV2D24 has been shown to be involved in the regulation of the immune system and has been implicated in the development and progression of autoimmune diseases.

IGKV2D24 has also been shown to play a role in the regulation of the activity of T-cells, which are a critical part of the immune system. IGKV2D24 has also been shown to play a role in the regulation of the activity of B-cells, which are responsible for producing antibodies as part of the immune response.

Potential Therapeutic Strategies

The IGKV2D24 gene has the potential to be a drug target and biomarker for a variety of neurodegenerative disorders, mental health conditions, and autoimmune diseases. Several potential therapeutic strategies have been identified for IGKV2D24, including:

1. Blockade of IGKV2D24: One potential therapeutic strategy is to block the activity of IGKV2D24 by using small molecules or antibodies that specifically target the IGKV2D24 gene. This approach could be used to treat neurodegenerative disorders and mental health conditions associated with IGKV2D24.
2.

Protein Name: Immunoglobulin Kappa Variable 2D-24 (non-functional)

Functions: Probable non-functional open reading frame (ORF) of V region of the variable domain of immunoglobulin light chains (PubMed:24600447). Non-functional ORF generally cannot participate in the synthesis of a productive immunoglobulin chain due to altered V-(D)-J or switch recombination and/or splicing site (at mRNA level) and/or conserved amino acid change (protein level) (PubMed:9619395). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets